Past, Present, and a Glance into the Future of Multiple Myeloma Treatment

Abstract

Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free survival for MM patients in the last decade; however, a relapse for most MM patients is inevitable. In this review we discuss current treatment, important pathways for proliferation, survival, immune suppression, and resistance that could be targeted for future treatments.

Keywords

• multiple myeloma
• B-cell malignancy
• bone marrow microenvironment
• drug resistance
• proteasome inhibitors
• immunotherapies